IgA Tarpeyo denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for iga tarpeyo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denies Tarpeyo as Non-Formulary — and Why That Denial Is Appealable

A non-formulary denial from UnitedHealthcare means Tarpeyo (budesonide delayed-release capsules for IgA nephropathy) is either not listed on your specific plan's drug formulary or is placed on a tier that requires prior authorization or is excluded entirely. Non-formulary status does not mean a drug is never covered — plans are generally required under ACA and ERISA rules to offer a formulary exception process when no formulary alternative is medically appropriate.

For Tarpeyo, a formulary exception is well-supported because IgA nephropathy has very few disease-modifying treatment options and because Tarpeyo's targeted mechanism is not replicated by typical formulary corticosteroids. The exception pathway exists precisely for situations like this.

## Your Federal Appeal Rights

• ACA formulary exception requirements: Non-grandfathered plans must have a formulary exception process. If UHC denies the exception, that denial itself constitutes an adverse benefit determination subject to internal appeal and external review under ACA §2719.
• ERISA §503: Employer-plan members may appeal any formulary exclusion decision as a denied claim.
• Timeline: After a final adverse determination on the formulary exception, you have the standard appeal windows — internal appeal typically within 180 days, external review for approximately four months after exhausting internal remedies. Use expedited review if kidney function is actively declining.

## Documentation to Gather Before You Appeal

1. Formulary alternative review — obtain UHC's current formulary and identify any drugs listed as alternatives. Your nephrologist should state in writing why each listed alternative is medically inappropriate or insufficient for your specific case. 2. Diagnosis and disease-severity documentation — biopsy report, laboratory trends, and nephrology notes confirming IgA nephropathy and clinical course. 3. Prior treatment history — any formulary drugs that were tried and failed, with dates, outcomes, and documented reasons for discontinuation. 4. Prescriber medical-necessity letter — a letter from your nephrologist explaining that no formulary drug adequately addresses your clinical needs and that Tarpeyo is medically necessary. 5. FDA label — attach the Tarpeyo prescribing label; the approved indication and mechanistic description support the argument that no formulary substitute is equivalent.

## Criteria-Mapping Structure

Your appeal letter should have two parts. First, address each formulary alternative by name and explain (per your nephrologist's letter) why it is not clinically interchangeable. Second, use a criteria table to show that your case meets UHC's formulary-exception criteria — typically: confirmed diagnosis, documented failure of or contraindication to formulary alternatives, and prescriber attestation of medical necessity. Attach all supporting documents as numbered exhibits referenced in the letter.